SEC For	rm 4																	
. ••••••					TATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549											OMB APPROVAL		
Section 16. Form 4 or Form 5 obligations may continue. See					d purs	D pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940								Estimated average burden hours per response:			11	
1. Name and Address of Reporting Person [*] Farkas Charles					2. Issuer Name and Ticker or Trading Symbol <u>CONMED Corp</u> [CNMD]								(Ch	5. Relationship of Repor (Check all applicable) X Director			orting Person(s) to Issuer 10% Owner	
	Last) (First) (Middle) C/O CONMED CORPORATION				3. Date of Earliest Transaction (Month/Day/Year) 06/01/2022									Officer (give title Other (specify below) below)				
11311 CONCEPT BOULEVARD				4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) LARGO														X Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(S	tate)	(Zip)															
		Tat	ole I - Nor	-Deriv	ative	e Se	curitie	s Ao	cquired,	Dis	posed o	f, or Bei	neficial	ly Owned				
Date						action 2A. Deemed Execution Date, if any (Month/Day/Yea			Code (Transaction Disposed Of (D) (Instr. 3, 4 Code (Instr. 5)				d 5. Amount of Securities Beneficially Owned Following Reported		Form: Direct I (D) or Indirect I (I) (Instr. 4)		7. Nature of ndirect Beneficial Dwnership Instr. 4)
									Code	v	Amount	ount (A) or (D) Pr		Transact (Instr. 3 a	tion(s)		ľ	
Common Stock 06/01/				1/202	2			М		812	A	\$ <u>0</u>	19,	243		D		
			Table II - I (luired, D s, optior					Owned				
1. Title of Derivative Security (Instr. 3)	ative Conversion Date Exe rity or Exercise (Month/Day/Year) if a		if any	Execution Date, Tr		ction Instr.	ı of ∣E		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Secur (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficia Owned Following Reported Transacti (Instr. 4)	e s illy g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisabl		Expiration Date	Title	Amount or Number of Shares					
Rsus (restricted Stock Units)	\$0	06/01/2022			м			812	06/01/2022	(1)	06/01/2031	Common Stock	812	\$0	0		D	
Options To Purchase Common Stock	\$111.79	06/01/2022			A		3,453		06/01/2023	(2)	06/01/2032	Common Stock	3,453	\$0	3,453	3	D	
Rsus (restricted Stock Units)	\$0	06/01/2022			A		335		06/01/2023	(1)	06/01/2032	Common Stock	335	\$0	335		D	

Explanation of Responses:

Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock, par value \$0.01 per share of ConMed Corporation (the "Company") and will be subject to the terms and conditions of the Company's 2020 Amended and Restated Non-Employee Director Equity Compensation Plan, with the RSUs generally vesting 100% after a one year period.
The stock options were granted under the Company's 2020 Amended and Restated Non-Employee Director Equity Compensation Plan and generally vest 100% after a one year period.

<u>Sarah M.</u> <u>Farkas by</u>		06/02/2022
	 _	

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.